0001415889-24-002388.txt : 20240202
0001415889-24-002388.hdr.sgml : 20240202
20240202181605
ACCESSION NUMBER: 0001415889-24-002388
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andriole Michael T.
CENTRAL INDEX KEY: 0001698751
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 24593230
MAIL ADDRESS:
STREET 1: C/O ENDOCYTE, INC.
STREET 2: 3000 KENT AVENUE, SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
form4-02022024_110200.xml
X0508
4
2024-02-01
0001117480
CHIMERIX INC
CMRX
0001698751
Andriole Michael T.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
true
true
false
false
PRESIDENT AND CEO
0
Common Stock
2024-02-01
4
A
0
83750
0
A
448765
D
Stock Option (Right to Buy)
.93
2024-02-01
4
A
0
502500
0
A
2034-01-31
Common Stock
502500
502500
D
The shares being reported are being issued pursuant to restricted unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 20,937 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 20,937 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 20,937 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 20,939 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant.
1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.
/s/ Michael Alrutz, Attorney-in-Fact
2024-02-02